Evidence map›Paper›PMID 40066114›Full record

ArticleIranian journal of pharmaceutical research : IJPR

Malleatin A and B: New Premyrsine-Type Diterpenes from

Behzad Zolfaghari, Forough Akbari, Sajad Esmaeili, Mahmoud Aghaei, Fatemeh Mosaffa, Seyedeh Sara Ghorbanhosseini, Mustafa Ghanadian

Abstract read
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Behzad ZolfaghariDepartment of Pharmaceutics, Novel Drug Delivery Systems Research Centre, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID https://orcid.org/0000-0001-7087-2590
Forough AkbariIsfahan Pharmaceutical Sciences Research center, Isfahan University of Medical Sciences, Isfahan, Iran.
Sajad EsmaeiliDepartment of Pharmaceutics, Novel Drug Delivery Systems Research Centre, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
Mahmoud AghaeiDepartment of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID https://orcid.org/0000-0002-1775-8761
Fatemeh MosaffaBiotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID https://orcid.org/0000-0001-7469-2773
Seyedeh Sara GhorbanhosseiniDepartment of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID https://orcid.org/0000-0002-1530-2955
Mustafa GhanadianPhytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0001-6446-4734

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This study focused on macrocyclic diterpenes derived from Euphorbia, particularly myrsinanes, and their potential in cytotoxic and combination treatments for resistant cancer cells. We examine premyrsinanes isolated from Methods: Results and Conclusions: Using a Waters 616 HPLC pump and a YMC prep silica column, we successfully isolated two new premyrsinane diterpenes (Malleatin A and Malleatin B) alongside two known compounds (beta-sitosterol and loliolide). Malleatin A exhibited cytotoxicity against A2780 wild and A2780 R-CIS cells, with an IC

Indexed as

Cisplatin ResistanceCombination TherapyDiterpeneEuphorbia malleataOvarian CancerPremyrsinane

Identifiers

PMID40066114
PMCPMC11892754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.